CNS Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders on April 30

TL;DR

<b>CNS Pharmaceuticals, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on April 30, 2024, to elect six directors.</b>

AI Summary

CNS Pharmaceuticals, Inc. (CNSP) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. The 2024 Annual Meeting of Stockholders for CNS Pharmaceuticals, Inc. will be held virtually on April 30, 2024, at 3:00 PM Eastern Daylight Time. Stockholders of record as of March 21, 2024, are eligible to vote. The meeting will allow for live listening, question submission, and online voting. The primary purpose of the meeting is to elect six nominees to the Board of Directors. Proxy materials, including the Proxy Statement and 2023 Annual Report on Form 10-K, are available electronically.

Why It Matters

For investors and stakeholders tracking CNS Pharmaceuticals, Inc., this filing contains several important signals. This meeting is a crucial opportunity for shareholders to exercise their voting rights and influence the company's future leadership and strategic direction. The virtual format aims to increase accessibility for stockholders to participate in important corporate governance decisions.

Risk Assessment

Risk Level: low — CNS Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate high risk.

Analyst Insight

Stockholders should review the proxy materials carefully and vote their shares to ensure their participation in the election of directors.

Key Numbers

• 6 — Board Nominees (Number of nominees to be elected to the Board of Directors)
• April 30, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders)
• March 21, 2024 — Record Date (Date to determine stockholders eligible to receive notice and vote)
• 3:00 P.M. EDT — Meeting Time (Time the Annual Meeting will commence)

Key Players & Entities

• CNS Pharmaceuticals, Inc. (company) — Registrant and filer of the proxy statement
• John Climaco (person) — Chief Executive Officer of CNS Pharmaceuticals, Inc.
• April 30, 2024 (date) — Date of the Annual Meeting of Stockholders
• March 21, 2024 (date) — Record date for determining stockholders eligible to vote
• 2024 (date) — Year of the Annual Meeting of Stockholders
• 2025 (date) — Year until which elected directors will serve

FAQ

Industry Context

CNS Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing treatments for central nervous system diseases.

Regulatory Implications

The filing is a standard DEF 14A (Definitive Proxy Statement) filed under the Securities Exchange Act of 1934, governing the solicitation of proxies from shareholders.

What Investors Should Do

1. Review the proxy statement for details on director nominees and proposals.
2. Vote your shares by proxy or in person at the virtual annual meeting.
3. Ensure your proxy card is completed, dated, and signed before returning.

Key Dates

• 2024-04-30: Annual Meeting of Stockholders — Election of directors and other corporate matters to be voted upon.
• 2024-03-21: Record Date — Determines which stockholders are entitled to receive notice and vote at the annual meeting.

Year-Over-Year Comparison

This filing is a Definitive Proxy Statement (DEF 14A) for the 2024 Annual Meeting, indicating a routine corporate governance event rather than a significant change from previous filings.

Key Financial Figures

• $1.28 — stock issued on October 16, 2023, from $1.28 per share to $0.30 per share and to ext
• $0.30 — tober 16, 2023, from $1.28 per share to $0.30 per share and to extend the termination
• $60,000 — le to InvestorCom will be approximately $60,000. WHERE ARE CNS&rsquo; PRINCIPAL EXECUT

Filing Documents

• cns_def14a.htm (DEF 14A) — 493KB
• image_001.jpg (GRAPHIC) — 157KB
• image_002.jpg (GRAPHIC) — 198KB
• 0001683168-24-002244.txt (&nbsp;) — 983KB

From the Filing

DEF 14A 1 cns_def14a.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant &uml; Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to &sect;240.14a-12 CNS Pharmaceuticals, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. o Fee paid previously with preliminary materials. o Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946-9185 To the Stockholders of CNS Pharmaceuticals, Inc.: You are cordially invited to attend the Annual Meeting of Stockholders of CNS Pharmaceuticals, Inc. on April 30, 2024. The Annual Meeting will begin at 3:00 P.M. Eastern Daylight Time virtually at https://agm.issuerdirect.com/cnsp where you will be able to listen to the meeting live, submit questions and vote online. Information regarding each of the matters to be voted on at the Annual Meeting is contained in the attached Proxy Statement and Notice of Annual Meeting of Stockholders. We urge you to read the proxy statement carefully. The proxy statement and proxy card are being mailed to all stockholders of record as of March 21, 2024. Because it is important that your shares be voted at the Annual Meeting, we urge you to complete, date and sign the enclosed proxy card and return it as promptly as possible in the accompanying envelope, whether or not you plan to attend. Even after returning your proxy, if you are a stockholder of record and do attend the meeting and wish to vote your shares in person, you still may do so. Very truly yours, CNS Pharmaceuticals, Inc. By: /s/ John Climaco John Climaco Chief Executive Officer Important Notice Regarding the Availability of Proxy Materials for the Annual Shareholder Meeting to be Held on April 30, 2024: Electronic Copies of the Proxy Statement and our 2023 Annual Report on Form 10-K are available at http://icomproxy.com/cnsp CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946-9185 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held April 30, 2024 TO THE STOCKHOLDERS OF CNS PHARMACEUTICALS, INC.: NOTICE IS HEREBY GIVEN that the 2024 Annual Meeting of Stockholders of CNS Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) will be held virtually at https://agm.issuerdirect.com/cnsp, on April 30, 2024 at 3:00 p.m. Eastern Daylight Time, for the following purposes, as described in the accompanying Proxy Statement: 1. To elect six Board nominees to the Board of Directors of the Company, each to serve until the 2025 annual meeting of stockholders of the Company or until such person&rsquo;s successor is qualified and elected. 2. To ratify the appointment of MaloneBailey, LLP as the Company&rsquo;s independent registered public accounting firm for the year ending December 31, 2024. 3. To grant our Board of Directors authority, in its sole discretion, prior to the one-year anniversary of this Annual Meeting, to effect a reverse stock split of the outstanding shares of the Company&rsquo;s common stock, at a reverse split ratio of between 1-for-2 and 1-for-50 as determined by the Board of Directors, by the filing of an amendment to the Company's Amended and Restated Articles of Incorporation. 4. To approve an amendment to the Company&rsquo;s Amended and Restated Articles of Incorporation to increase the total number of authorized shares of common stock from 75,000,000 shares to 300,000,000 shares. 5. To approve amendments to the Company's 2020 Stock Plan including an increase in the number of shares of common stock authorized for issuance under the Company's 2020 Stock Plan. 6. To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the repricing of certain warrants to purchase up to 3,756,000 shares of common stock issued on October 16, 2023, from $1.28 per share to $0.30 per share and to extend the termination date of such warrants to February 1, 2029. 7. To authorize the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the above proposals. Only stockholders of record of the Company at the close of business on March 21, 2024, are entitled to notice of and to vote at the Annual Meeting or any adjournment or postpon